Kura Oncology(US:KURA) ZACKS·2026-03-05 13:41分组1 - Kura Oncology reported a quarterly loss of $0.92 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.72, and a significant increase from a loss of $0.22 per share a year ago, resulting in an earnings surprise of -28.67% [1] - The company posted revenues of $17.34 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 41.85%, and a decline from year-ago revenues of $53.88 million [2] - Kura Oncology shares have decreased by approximately 17.7% since the beginning of the year, contrasting with the S&P 500's gain of 0.4% [3] 分组2 - The earnings outlook for Kura Oncology is uncertain, with current consensus EPS estimates at -$0.95 on $18.37 million in revenues for the coming quarter and -$3.08 on $175.32 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 46% of over 250 Zacks industries, indicating that the industry outlook may negatively impact stock performance [8] - The estimate revisions trend for Kura Oncology was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]